- TRADE NAME: Retevmo (Loxo Oncology Inc)
- INDICATIONS:
Non-small cell lung cancer; thyroid cancer.
Note: (2020) FDA approved under accelerated approval based on overall response rate and duration of response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- CLASS: Kinase inhibitor, RET (Rearranged during Transfection) kinase inhibitor
- HALF-LIFE: 32 hours
- FDA APPROVAL DATE: 05/08/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
acid-reducing agents (proton pump inhibitors, H2 receptor antagonists, locally-acting antacids), CYP2C8 and CYP3A substrates, CYP3A inducers, CYP3A inhibitors, Itraconazole, Midazolam, Omeprazole, Repaglinide, Rifampin - PREGNANCY: Can cause fetal harm. Advise females of reproductive potential of the possible risk to the fetus and to use effective contraception.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 04/18/2025
